Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems

BMC Medical Genomics

Volumn 8, Issue 1, 2015, Pages

  Eriksson, Pontus ^a   Aine, Mattias ^a   Veerla, Srinivas ^a   Liedberg, Fredrik ^b   Sjödahl, Gottfrid ^b   Höglund, Mattias ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Bladder cancer; Gene signatures; Molecular subtypes; Transcription factor; Urothelial carcinoma

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ADIRF; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; FATTY ACID; LIPID; PROTEIN BINDING; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID METABOLISM; GENE; GENE CONTROL; GENETIC STABILITY; GENETIC VARIABILITY; HOXA GENE; HOXB GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; UPREGULATION; ANIMAL; BINDING SITE; BIOLOGY; BLADDER TUMOR; CARCINOMA; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; SOFTWARE; TUMOR CELL LINE; UROTHELIUM;

ANIMALS; BINDING SITES; BIOMARKERS, TUMOR; CARCINOMA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; FATTY ACIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPIDS; MICE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SOFTWARE; TRANSCRIPTION, GENETIC; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84930208685     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/s12920-015-0101-5     Document Type: Article

References (59)

1. Shin K, Lee J, Guo N, Kim J, Lim A, Qu L, et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472(7341):110-4. doi:10.1038/nature09851.
2. DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2013;31(6):802-11. doi:10.1016/j.urolonc.2011.07.017.
3. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377-86. doi:10.1158/1078-0432.CCR-12-0077-T.
4. Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol. 2013;183(3):681-91. doi:10.1016/j.ajpath.2013.05.013.
5. Eriksson P, Aine M, Sjodahl G, Staaf J, Lindgren D, Hoglund M. Detailed analysis of focal chromosome arm 1q and 6p amplifications in urothelial carcinoma reveals complex genomic events on 1q and as a possible auxiliary target on 6p. PLoS One. 2013;8(6):e67222. doi:10.1371/journal.pone.0067222.
6. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012;7(6):e38863. doi:10.1371/journal.pone.0038863.
7. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110-5. doi:10.1073/pnas.1318376111.
8. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3. doi:10.1186/1476-4598-9-3.
9. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22. doi:10.1038/nature12965.
10. The Cancer Genome Atlas Research Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi: 10.1038/nature11412.
11. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74. doi:10.1038/nature11247.
12. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, et al. Software for computing and annotating genomic ranges. PLoS Comput Biol. 2013;9(8):e1003118. doi:10.1371/journal.pcbi.1003118.
13. Tang Q, Chen Y, Meyer C, Geistlinger T, Lupien M, Wang Q, et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res. 2011;71(22):6940-7. doi:10.1158/0008-5472.CAN-11-2091.
14. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011;12(8):R83. doi:10.1186/gb-2011-12-8-r83.
15. Kittler R, Zhou J, Hua S, Ma L, Liu Y, Pendleton E, et al. A comprehensive nuclear receptor network for breast cancer cells. Cell Rep. 2013;3(2):538-51. doi:10.1016/j.celrep.2013.01.004.
16. Donaldson IJ, Amin S, Hensman JJ, Kutejova E, Rattray M, Lawrence N, et al. Genome-wide occupancy links Hoxa2 to Wnt-beta-catenin signaling in mouse embryonic development. Nucleic Acids Res. 2012;40(9):3990-4001. doi:10.1093/nar/gkr1240.
17. Mudunuri U, Che A, Yi M, Stephens RM. bioDBnet: the biological database network. Bioinformatics. 2009;25(4):555-6. doi:10.1093/bioinformatics/btn654.
18. Veerla S, Ringner M, Hoglund M. Genome-wide transcription factor binding site/promoter databases for the analysis of gene sets and co-occurrence of transcription factor binding motifs. BMC Genomics. 2010;11:145. doi:10.1186/1471-2164-11-145.
19. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 2006;34(Database issue):D108-10. doi:10.1093/nar/gkj143.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98(9):5116-21. doi:10.1073/pnas.091062498.
21. Neph S, Vierstra J, Stergachis AB, Reynolds AP, Haugen E, Vernot B, et al. An expansive human regulatory lexicon encoded in transcription factor footprints. Nature. 2012;489(7414):83-90. doi:10.1038/nature11212.
22. Bock M, Hinley J, Schmitt C, Wahlicht T, Kramer S, Southgate J. Identification of ELF3 as an early transcriptional regulator of human urothelium. Dev Biol. 2014;386(2):321-30. doi:10.1016/j.ydbio.2013.12.028.
23. Varley CL, Bacon EJ, Holder JC, Southgate J. FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation. Cell Death Differ. 2009;16(1):103-14. doi: 10.1038/cdd.2008.116.
24. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572-3. doi:10.1093/bioinformatics/btq170.
25. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011;1812(8):1007-22. doi:10.1016/j.bbadis.2011.02.014.
26. Ni Y, Ji C, Wang B, Qiu J, Wang J, Guo X. A Novel pro-adipogenesis factor abundant in adipose tissues and over-expressed in obesity acts upstream of PPARgamma and C/EBPalpha. J Bioenerg Biomembr. 2013;45(3):219-28. doi: 10.1007/s10863-012-9492-6.
27. Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q, Turkson J. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One. 2011;6(5):e19605. doi:10.1371/journal.pone.0019605.
28. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-25.
29. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galvan P, et al. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep. 2013;3:3544. doi:10.1038/srep03544.
30. Sadasivam S, Duan S, DeCaprio JA. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev. 2012;26(5):474-89. doi:10.1101/gad.181933.111.
31. Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol. 2008;10(9):1076-82. doi:10.1038/ncb1767.
32. Banaszak L, Winter N, Xu Z, Bernlohr DA, Cowan S, Jones TA. Lipid-binding proteins: a family of fatty acid and retinoid transport proteins. Adv Protein Chem. 1994;45:89-151.
33. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell. 2007;129(4):723-33. doi:10.1016/j.cell.2007.02.050.
34. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci U S A. 2008;105(21):7546-51. doi:10.1073/pnas.0709981105.
35. Aine M, Sjodahl G, Eriksson P, Veerla S, Lindgren D, Ringner M, et al. Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma. Genome Med. 2015;7(1):23. doi:10.1186/s13073-015-0144-4.
36. Mauney JR, Ramachandran A, Yu RN, Daley GQ, Adam RM, Estrada CR. All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms. PLoS One. 2010;5(7):e11513. doi:10.1371/journal.pone.0011513.
37. Varley CL, Stahlschmidt J, Lee WC, Holder J, Diggle C, Selby PJ, et al. Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci. 2004;117(Pt 10):2029-36. doi:10.1242/jcs.01042.
38. Ballim RD, Mendelsohn C, Papaioannou VE, Prince S. The ulnar-mammary syndrome gene, Tbx3, is a direct target of the retinoic acid signaling pathway, which regulates its expression during mouse limb development. Mol Biol Cell. 2012;23(12):2362-72. doi:10.1091/mbc.E11-09-0790.
39. Boskovic G, Niles RM. T-box binding protein type two (TBX2) is an immediate early gene target in retinoic-acid-treated B16 murine melanoma cells. Exp Cell Res. 2004;295(2):281-9. doi:10.1016/j.yexcr.2003.12.017.
40. Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2 and ZIC4 as pTa-specific prognostic markers. Eur Urol. 2012;61(6):1245-56. doi:10.1016/j.eururo.2012.01.011.
41. Poulsen L, Siersbaek M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol. 2012;23(6):631-9. doi:10.1016/j.semcdb.2012.01.003.
42. Strand DW, Jiang M, Murphy TA, Yi Y, Konvinse KC, Franco OE, et al. PPARgamma isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation. Cell Death Dis. 2012;3:e361. doi:10.1038/cddis.2012.99.
43. Ho PL, Lay EJ, Jian W, Parra D, Chan KS. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 2012;72(13):3135-42. doi:10.1158/0008-5472.CAN-11-3195.
44. Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, et al. Deficiency in metabolic regulators PPARgamma and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am J Pathol. 2013;182(2):449-59. doi:10.1016/j.ajpath.2012.10.007.
45. Varley CL, Stahlschmidt J, Smith B, Stower M, Southgate J. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol. 2004;164(5):1789-98.
46. Chen X, Muller GA, Quaas M, Fischer M, Han N, Stutchbury B, et al. The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol. 2013;33(2):227-36. doi:10.1128/MCB.00881-12.
47. Carr JR, Kiefer MM, Park HJ, Li J, Wang Z, Fontanarosa J, et al. FoxM1 regulates mammary luminal cell fate. Cell Rep. 2012;1(6):715-29. doi:10.1016/j.celrep.2012.05.005.
48. Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H, Teh MT. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res. 2010;70(22):9515-26. doi:10.1158/0008-5472.CAN-10-2173.
49. Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res. 2011;71(13):4329-33. doi:10.1158/0008-5472.CAN-11-0640.
50. Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer. 2010;9:45. doi:10.1186/1476-4598-9-45.
51. He X, Marchionni L, Hansel DE, Yu W, Sood A, Yang J, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells. 2009;27(7):1487-95. doi:10.1002/stem.92.
52. Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Perez C, et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and Basal subtypes. Cell Rep. 2014;9(4):1235-45. doi:10.1016/j.celrep.2014.10.035.
53. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152-65. doi:10.1016/j.ccr.2014.01.009.
54. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20(9):1123-36. doi:10.1101/gad.381706.
55. Kashyap V, Gudas LJ, Brenet F, Funk P, Viale A, Scandura JM. Epigenomic reorganization of the clustered Hox genes in embryonic stem cells induced by retinoic acid. J Biol Chem. 2011;286(5):3250-60. doi:10.1074/jbc.M110.157545.
56. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004;18(2):126-31. doi:10.1101/gad.1165104.
57. Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A. 2012;109(6):2078-83. doi:10.1073/pnas.1120605109.
58. Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, et al. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 2013;32(5):554-63. doi:10.1038/onc.2012.62.
59. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127(5):1041-55. doi:10.1016/j.cell.2006.09.048.